CD40 and glioblastoma: Knowing the fact that in glioblastoma, upregulation of the CD40/CD40L axis is an indicator for better prognosis, it is interesting that in vivo, the use of this anti-CD40 agonist antibody actually shows anti-tumor effects [85,87].